FEDERAL AGRICULTURAL MORTGAGE CORP
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
AGM$181.57+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Other | ||||||||
| Preferred Stock · Common Stock · Paid-In · Comprehensive · Retained · Total | ||||||||
| Shares | Amount | Shares | Amount | Capital | Income/(Loss) | Earnings | Equity | |
| (in thousands) | ||||||||
| Balance as of December 31, 2025 | 20,980 | $507,993 | 10,857 | $10,857 | $139,370 | $13,382 | $1,047,347 | $1,718,949 |
| Net Income | — | — | — | — | — | — | 59,123 | 59,123 |
| Other comprehensive loss, net of tax | — | — | — | — | — | (28,453) | — | (28,453) |
| Dividends: | ||||||||
| Preferred stock | — | — | — | — | — | — | (7,291) | (7,291) |
| Common stock (cash dividend of $1.60 per share) | — | — | — | — | — | — | (17,341) | (17,341) |
| Repurchase of Class C Common Stock | — | — | (47) | (47) | — | — | (7,131) | (7,178) |
| Issuance of Class C Common Stock | — | — | 39 | 39 | 60 | — | — | 99 |
| Stock-based compensation cost | — | — | — | — | 3,004 | — | — | 3,004 |
| Other stock-based award activity | — | — | — | — | (3,891) | — | — | (3,891) |
| Balance as of March 31, 2026 | 20,980 | $507,993 | 10,849 | $10,849 | $138,543 | $(15,071) | $1,074,707 | $1,717,021 |
| Net Income | — | — | — | — | — | — | 66,951 | 66,951 |
| Other comprehensive loss, net of tax | — | — | — | — | — | (3,163) | — | (3,163) |
| Dividends: | ||||||||
| Preferred stock | — | — | — | — | — | — | (8,074) | (8,074) |
| Common stock (cash dividend of 1.60 per share) | — | — | — | — | — | — | (17,359) | (17,359) |
| Issuance of Series I Preferred Stock | 4,000 | 96,764 | — | — | — | — | — | 96,764 |
| Issuance of Class C Common Stock | — | — | 1 | 1 | 61 | — | — | 62 |
| Stock-based compensation cost | — | — | — | — | 2,323 | — | — | 2,323 |
| Other stock-based award activity | — | — | — | — | (91) | — | — | (91) |
| Balance as of June 30, 2026 | 24,980 | $604,757 | 10,850 | $10,850 | $140,836 | $(18,234) | $1,116,225 | $1,854,434 |
| Balance as of December 31, 2024 | 16,980 | $411,149 | 10,891 | $10,891 | $135,894 | $(12,147) | $943,239 | $1,489,026 |
| Net Income | — | — | — | — | — | — | 49,651 | 49,651 |
| Other comprehensive income, net of tax | — | — | — | — | — | 10,339 | — | 10,339 |
| Dividends: | ||||||||
| Preferred stock | — | — | — | — | — | — | (5,666) | (5,666) |
| Common stock (cash dividend of $1.50 per share) | — | — | — | — | — | — | (16,352) | (16,352) |
| Issuance of Class C Common Stock | — | — | 42 | 42 | 79 | — | — | 121 |
| Stock-based compensation cost | — | — | — | — | 3,529 | — | — | 3,529 |
| Other stock-based award activity | — | — | — | — | (5,002) | — | — | (5,002) |
| Balance as of March 31, 2025 | 16,980 | $411,149 | 10,933 | $10,933 | $134,500 | $(1,808) | $970,872 | $1,525,646 |
| Net Income | — | — | — | — | — | — | 54,837 | 54,837 |
| Other comprehensive income, net of tax | — | — | — | — | — | (15,857) | — | (15,857) |
| Dividends: | ||||||||
| Preferred stock | — | — | — | — | — | — | (5,667) | (5,667) |
| Common stock (cash dividend of $1.50 per share) | — | — | — | — | — | — | (16,401) | (16,401) |
| Issuance of Class C Common Stock | — | — | 1 | 1 | 80 | — | — | 81 |
| Stock-based compensation cost | — | — | — | — | 1,745 | — | — | 1,745 |
| Other stock-based award activity | — | — | — | — | (77) | — | — | (77) |
| Balance as of June 30, 2025 | 16,980 | $411,149 | 10,934 | $10,934 | $136,248 | $(17,665) | $1,003,641 | $1,544,307 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.